[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340780-105":59,"doc-detail-340780-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","antitumor-activity-of-afatinib-in-egfrt790m-negative-human-oral-cancer-therapeutically-targets-mtormcl-1-signaling-axis","Antitumor activity of afatinib in EGFRT790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis","","Purpose examines the role and effectiveness of EGFR tyrosine kinase inhibitor therapy in oral cancer, emphasizing the clinical relevance of EGFR and myeloid cell leukemia-1 (Mcl-1) in head and neck cancers. Methods integrate in silico analyses from TCGA, GEO, and CPTAC with immunohistochemistry plus in vitro and in vivo assays, including apoptosis, signaling assessment, expression studies, and a tumor xenograft model. Results show EGFR/Mcl-1 co-expression predicts poor prognosis, while afatinib induces apoptosis and suppresses Mcl-1 via the EGFR/mTOR/Mcl-1 axis, reducing tumor volume. Conclusion supports afatinib as a promising therapeutic strategy, particularly for high EGFR and Mcl-1 expression.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/antitumor-activity-of-afatinib-in-egfrt790m-negative-human-oral-cancer-therapeutically-targets-mtormcl-1-signaling-axis/340780/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/antitumor-activity-of-afatinib-in-egfrt790m-negative-human-oral-cancer-therapeutically-targets-mtormcl-1-signaling-axis/340780.png","ImageObject",300,407,{"name":92,"@type":93},"Valentina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of the study on afatinib in oral cancer?","Question",{"text":112,"@type":113},"To investigate the clinical relevance of EGFR and Mcl-1 in head and neck cancers and to explore the molecular mechanism and effectiveness of afatinib, an EGFR TKI, in treating human oral cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did the researchers study EGFR and Mcl-1 and test afatinib’s effects?",{"text":117,"@type":113},"They used in silico analyses with TCGA, GEO, and CPTAC, immunohistochemistry, and a range of in vitro and in vivo experiments including apoptosis and protein/signaling assays plus a tumor xenograft model.",{"name":119,"@type":110,"acceptedAnswer":120},"What results link EGFR/Mcl-1 expression to patient prognosis and what did afatinib do?",{"text":121,"@type":113},"EGFR and Mcl-1 were higher in HNC tissues than normal tissues, and their co-expression correlated with poor prognosis. Afatinib induced apoptosis and suppressed Mcl-1 in oral cancer cells without the EGFR T790M mutation, leading to reduced tumor volume.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340780,1790194384,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Cellular Oncology (2025) 48:123–138  \n[https://doi.org/10.1007/s13402-024-00962-6](https://doi.org/10.1007/s13402-024-00962-6)  \nRESEARCH  \nAntitumor activity of afatinib in EGFRT790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis  \nJung-Min Han1 · Kyu-Young Oh2 · Su-Jung Choi1 · Won-Woo Lee3 · Bo-Hwan Jin3 · Ji-Hoon Kim1 · Hyun-Ju Yu1 · Ryan Jin Young Kim4 · Hye-Jung Yoon1 · Jae-Il Lee1 · Seong-Doo Hong1 · Sung-Dae Cho1  \nAccepted: 20 May 2024 / Published online: 18 June 2024 © The Author(s) 2024  \nAbstract  \nPurpose This study investigates the role and effectiveness of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in oral cancer, focusing on the clinical relevance of EGFR and myeloid cell leukemia-1 (Mcl-1) in head and neck cancers (HNCs). It aims to explore the molecular mechanism of afatinib, a TKI, in treating human oral cancer. Methods We conducted an in silico analysis using databases like The Cancer Genome Atlas, Gene Expression Omnibus, and Clinical Proteomic Tumor Analysis Consortium, along with immunohistochemistry staining, to study EGFR and Mcl-1 expression in HNCs. For investigating afatinib’s anticancer properties, we performed various in vitro and in vivo analyses, including trypan blue exclusion assay, Western blotting, 4′-6-diamidino-2-phenylindole staining, flow cytometry, quantitative real-time PCR, Mitochondrial membrane potential assay, overexpression vector construction, transient transfection, anda tumor xenograft model.  \nResults Higher expression levels of EGFR and Mcl-1 were observed in HNC patient tissues compared to normal tissues, with their co-expression significantly linked to poor prognosis. There was a strong correlation between EGFR and Mcl-1 expressions in oral cancer patients. Afatinib treatment induced apoptosis and suppressed Mcl-1 in oral cancer cell lines without the EGFR T790M mutation. The mechanism of afatinib-induced apoptosis involved the EGFR/mTOR/Mcl-1 axis, as shown by the effects of mTOR activator MHY1485 and inhibitor rapamycin. Afatinib also increased Bim expression, mitochondrial membrane permeabilization, and cytochrome c release. It significantly lowered tumor volume without affecting body, liver, and kidney weights.  \nConclusion Afatinib, targeting the EGFR/mTOR/Mcl-1 axis, shows promise as a therapeutic strategy for oral cancer, especially in patients with high EGFR and Mcl-1 expressions.  \nKeywords Head and neck cancer · Afatinib · Epidermal growth factor receptor · Myeloid cell leukemia-1 · Mammalian target of rapamycin  \n􀀍 Seong-Doo Hong [hongsd@snu.ac.kr](hongsd@snu.ac.kr)  \n􀀍 Sung-Dae Cho [efiwdsc@snu.ac.kr](efiwdsc@snu.ac.kr)  \n1 Department of Oral Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul 03080, Republic of Korea  \n2 Department of Oral Pathology, College of Dentistry, Dankook University, Cheonan 31116, Republic of Korea  \n3 Laboratory Animal Center, CHA University, CHA Biocomplex, Sampyeong-Dong, Seongnam 13488, Republic of Korea  \n4 Department of Dental Science, School of Dentistry and Dental Research Institute, Seoul National University, Seoul 03080, Republic of Korea  \n1 Introduction  \nEpidermal growth factor receptor (EGFR), which is a transmembrane receptor tyrosine kinase (RTK) with a molecular weight of 170 kDa and is a member of the human epidermal growth factor receptor (HER) family, plays a key role in the maintenance of epithelial tissue [1] . During organogenesis and tissue regeneration, the EGFR normally provides a robust signal for epithelial cell growth and survival by binding of ligands on the cell surface, leading to homoor hetero-dimerization and inducing its activation [2, 3] . Pathologically, EGFR’s role in the development of human cancers through its dysregulation, including its overexpression, overproduction of its ligands, and altered triggering of  \nits tyrosine kinase domain (TKD) activity by point mutation, has been well studie","cbCaimBNaxWXU9N9","https://ap.wps.com/l/cbCaimBNaxWXU9N9","pdf",10383671,16,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Results\n## High co-expressions of EGFR and myeloid cell leukemia-1 (Mcl-1) are associated with a poor prognosis","[{\"question\":\"What is the main purpose of the study on afatinib in oral cancer?\",\"answer\":\"To investigate the clinical relevance of EGFR and Mcl-1 in head and neck cancers and to explore the molecular mechanism and effectiveness of afatinib, an EGFR TKI, in treating human oral cancer.\"},{\"question\":\"How did the researchers study EGFR and Mcl-1 and test afatinib’s effects?\",\"answer\":\"They used in silico analyses with TCGA, GEO, and CPTAC, immunohistochemistry, and a range of in vitro and in vivo experiments including apoptosis and protein/signaling assays plus a tumor xenograft model.\"},{\"question\":\"What results link EGFR/Mcl-1 expression to patient prognosis and what did afatinib do?\",\"answer\":\"EGFR and Mcl-1 were higher in HNC tissues than normal tissues, and their co-expression correlated with poor prognosis. Afatinib induced apoptosis and suppressed Mcl-1 in oral cancer cells without the EGFR T790M mutation, leading to reduced tumor volume.\"}]","Antitumor activity of afatinib in EGFRT790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis | PDF",1790038873,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4bcdc59bfdbf71aadc9e146266b9f15.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e006507ae5d5b391a2c34b66de30cd4b.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c12ce2b8ed42cd958a2530d3d43feadd.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e90802cb9f597ad6e315c8d15445dc89.webp",980,1301]